Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TS-172 in patients with hepatic impairment
NCT07231029Phase 1Recruiting
- Sponsor
- Taisho Pharmaceutical
- Start
- Dec 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TS-172 in hyperphosphatemia (3 arms), sponsored by Taisho Pharmaceutical. Primary endpoint: Plasma concentrations of unchanged form and metabolites at 48 hours. Started Dec 2025; status: recruiting.
02
Drugs
TS-172
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT07231029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07231029.